It's hard to look good when you are in a hostile environment, but the seven pharma CEOs set to appear before the Senate Finance Committee on Feb. 26 are going to need to try – both for their own sake and for the industry as a whole.
The outcome of the hearing may set the tone for legislative and public relations attacks against pharma for years to...